Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | DRD3 | P35462 | 6/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404673 | 0.87 | DRD3 (0.65) | NAMPTPARP1DRD2DRD3KCNA5 | |
| SCHEMBL19634400 | 0.86 | ALDH1A1 (0.62) | NAMPTDRD2ALDH1A1POLBMEN1 | |
| SCHEMBL15947381 | 0.84 | NAMPT (0.58) | NAMPTPARP1DRD2DRD3KCNA5 | |
| SCHEMBL19634738 | 0.84 | DRD3 (0.52) | DRD2DRD3KCNA5MEN1KMT2A | |
| SCHEMBL14853580 | 0.81 | NAMPT (0.55) | NAMPTPARP1DRD2DRD3KCNA5 | |
| SCHEMBL12976185 | 0.81 | SMN1; SMN2 (0.56) | DRD2DRD3ALDH1A1POLBMEN1 | |
| SCHEMBL20458263 | 0.80 | NAMPT (0.54) | NAMPTPARP1DRD2DRD3KCNA5 | |
| SCHEMBL19634739 | 0.78 | DRD3 (0.55) | DRD2DRD3KCNA5 | |
| SCHEMBL20203277 | 0.78 | DRD2 (0.51) | NAMPTDRD2DRD3KCNA5ALDH1A1 | |
| SCHEMBL8543987 | 0.78 | NAMPT (0.52) | NAMPTPARP1DRD2DRD3KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | NAMPT 980/4885PARP1 987/4885DRD2 3480/4885 |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | NAMPT 980/4885PARP1 987/4885DRD2 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.